Gregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $16.34, for a total transaction of $163,400.00. Following the transaction, the insider now directly owns 134,021 shares in the company, valued at approximately $2,189,903.14. The trade was a 6.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $14.59 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm has a market cap of $1.92 billion, a P/E ratio of -9.54 and a beta of 1.54. The firm’s 50 day moving average price is $16.48 and its 200-day moving average price is $16.41. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04. As a group, equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on CNTA. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Guggenheim reissued a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $26.00.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in shares of Centessa Pharmaceuticals by 88.1% in the third quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock valued at $4,237,000 after purchasing an additional 124,075 shares during the period. FMR LLC grew its stake in shares of Centessa Pharmaceuticals by 4.6% in the third quarter. FMR LLC now owns 2,916,494 shares of the company’s stock worth $46,635,000 after acquiring an additional 129,300 shares in the last quarter. Ally Bridge Group NY LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth $4,951,000. Suvretta Capital Management LLC acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at $1,119,000. Finally, Walleye Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at $187,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.